We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04330586
Recruitment Status : Completed
First Posted : April 1, 2020
Last Update Posted : June 24, 2021
Information provided by (Responsible Party):
Woo Joo Kim, Korea University Guro Hospital

Brief Summary:
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Ciclesonide Metered Dose Inhaler [Alvesco] Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm (standard care)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
Actual Study Start Date : April 1, 2020
Actual Primary Completion Date : March 31, 2021
Actual Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Ciclesonide

Arm Intervention/treatment
Experimental: Ciclesonide
Ciclesonide 320ug oral inhalation q12h for 14 days
Drug: Ciclesonide Metered Dose Inhaler [Alvesco]
Ciclesonide 320ug oral inhalation q12h for 14 days

No Intervention: Control
Standard care without ciclesonide

Primary Outcome Measures :
  1. Rate of SARS-CoV-2 eradication at day 14 from study enrollment [ Time Frame: Hospital day 14 ]
    Viral load

Secondary Outcome Measures :
  1. Rate of SARS-CoV-2 eradication at day 7 from study enrollment [ Time Frame: Hospital day 7 ]
    Viral load

  2. Time to SARS-CoV-2 eradication (days) [ Time Frame: Hospital day 1, 4, 7, 10, 14, 21 ]
    Viral load

  3. Viral load area-under-the-curve (AUC) reduction versus control [ Time Frame: Hospital day 1, 4, 7, 10, 14, 21 ]
    Viral load change

  4. Time to clinical improvement (days) [ Time Frame: Up to 28 days ]
    Resolution of all systemic and respiratory symptoms for ≥2 consecutive days

  5. Proportion of clinical failure [ Time Frame: Up to 28 days ]
    High-flow oxygen therapy or mechanical ventilation requiring salvage therapy

Other Outcome Measures:
  1. Safety and tolerability of study drug [ Time Frame: Up to 28 days ]
    Number of adverse events, proportion of early discontinuance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with mild COVID-19 (NEWS scoring system 0-4)
  • Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)

Exclusion Criteria:

  • Hypoxia (SaO2 <95%)
  • Unable to take oral medication
  • Unable to use inhaler
  • Pregnancy or breast feeding
  • Immunocompromising conditions
  • Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min
  • Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit
  • Asthma or chronic obstructive lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04330586

Layout table for location information
Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University Guro Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Woo Joo Kim, Professor, Korea University Guro Hospital
ClinicalTrials.gov Identifier: NCT04330586    
Other Study ID Numbers: KUMC-COVID-19
First Posted: April 1, 2020    Key Record Dates
Last Update Posted: June 24, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Woo Joo Kim, Korea University Guro Hospital:
Viral load
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents